<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C6BF93FE-5C2F-472A-B6FC-00A9E38121DB"><gtr:id>C6BF93FE-5C2F-472A-B6FC-00A9E38121DB</gtr:id><gtr:name>School of Public Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9AADEFF2-5583-4E99-8B3A-B2E08CF0D6FF"><gtr:id>9AADEFF2-5583-4E99-8B3A-B2E08CF0D6FF</gtr:id><gtr:name>Illumina Inc.</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EF81E361-38CE-4E62-A3AA-ADE0AE13B796"><gtr:id>EF81E361-38CE-4E62-A3AA-ADE0AE13B796</gtr:id><gtr:name>European Molecular Biology Lab (EMBL)</gtr:name><gtr:department>Finance</gtr:department><gtr:address><gtr:line1>EMBL Heidlberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:line5>D-69117</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EF81E361-38CE-4E62-A3AA-ADE0AE13B796"><gtr:id>EF81E361-38CE-4E62-A3AA-ADE0AE13B796</gtr:id><gtr:name>European Molecular Biology Lab (EMBL)</gtr:name><gtr:address><gtr:line1>EMBL Heidlberg</gtr:line1><gtr:line4>Heidelberg</gtr:line4><gtr:line5>D-69117</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C6BF93FE-5C2F-472A-B6FC-00A9E38121DB"><gtr:id>C6BF93FE-5C2F-472A-B6FC-00A9E38121DB</gtr:id><gtr:name>School of Public Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9AADEFF2-5583-4E99-8B3A-B2E08CF0D6FF"><gtr:id>9AADEFF2-5583-4E99-8B3A-B2E08CF0D6FF</gtr:id><gtr:name>Illumina Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/842CDF34-01CE-4E95-88A5-E02AC347106D"><gtr:id>842CDF34-01CE-4E95-88A5-E02AC347106D</gtr:id><gtr:firstName>Ewan</gtr:firstName><gtr:surname>Birney</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0300762"><gtr:id>3CF34D59-A0D3-4B41-8F7C-A063F5E30027</gtr:id><gtr:title>Bioinformatics for the Analysis and Exploitation of Resequenced Genomes (BARGEN)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300762</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-06-25</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-06-26</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>214264</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Illumina Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Illumina (Formerly Solexa)</gtr:description><gtr:id>273000BD-717F-451F-AB76-EE54CCD12B89</gtr:id><gtr:impact>We now regularly exchange software components and ideas in both directions</gtr:impact><gtr:partnerContribution>Sharing of programming code and experience, early access to data and instruments</gtr:partnerContribution><gtr:piContribution>Collaboration on software tools - We now regularly exchange software components and ideas in both directions</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Public Health</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Epidemiology and Biostatistics</gtr:department><gtr:description>David Balding</gtr:description><gtr:id>348F4A68-76B6-4541-905B-384B822880BC</gtr:id><gtr:impact>More complex genetic alogorthms</gtr:impact><gtr:partnerContribution>A deeper understanding of population genetics information in designing analysis methods</gtr:partnerContribution><gtr:piContribution>An understanding of sequence information</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk to House of Lords</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C804126B-4BE3-4CAB-8161-3AEE4D565E8C</gtr:id><gtr:impact>Gave evidence at House of Lords panel on genomics in health

Informed policy makers of next generation sequencing technology aspects</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to Illumina community</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>096F3C3D-35CD-484B-BC25-C6AA884D62E4</gtr:id><gtr:impact>Provided a talk to next generation sequencing forums

Provided new collaborators</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>7000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>380241AA-FB66-4009-B126-13F54E06372D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HouseOfLords</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>19166CB0-34F6-4C47-BD04-C3689FEC7279</gtr:id><gtr:impact>Exploring the potential future aspects fo genomics, in particular with respect to IT</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Resembl- a resequencing platform working with Ensembl and Velvet, a de-novo assembler</gtr:description><gtr:id>2B6F9788-B543-486F-8874-E8E8307E5E2A</gtr:id><gtr:impact>extended the use of ultra high throughput sequencing to more people</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Resequencing</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Does assembly using short read (next generation) sequence</gtr:description><gtr:id>D53DC79E-25EA-45F1-BA03-82C4DB53DE28</gtr:id><gtr:impact>This is one of the most heavily used software components for short read assembly in bacteria</gtr:impact><gtr:title>Velvet Assembler</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D029462B-4DBC-4C21-B4E7-BD4C504D417D"><gtr:id>D029462B-4DBC-4C21-B4E7-BD4C504D417D</gtr:id><gtr:title>Velvet: algorithms for de novo short read assembly using de Bruijn graphs.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8f2d438575d300d51c13ce2d6307115e"><gtr:id>8f2d438575d300d51c13ce2d6307115e</gtr:id><gtr:otherNames>Zerbino DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300762</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>12A0B409-0C29-4056-9092-2D86E44017F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.4  Methodologies and measurements</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>